Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Afirma thyroid FNA analysis (Veracyte) Lansdale: HAYES, Inc. Genetic Testing Publication. 2017 Authors' conclusions In recent years, significant advances in understanding the genetic mechanisms of thyroid cancer have changed the way thyroid nodules are treated clinically. Several molecular targets have been associated with malignancy, including microRNA (miRNA), a noncoding endogenous form of RNA that helps regulate gene expression. Previous investigations have detected the dysregulation of miRNAs in malignant thyroid nodules, identifying the potential role of miRNAs in differentiating benign thyroid nodules from malignant ones. The Afirma Thyroid FNA Analysis is a diagnostic service that includes thyroid-specialized cytopathology and gene expression testing for the analysis of FNA thyroid nodule biopsies. This report examines the published evidence regarding the Afirma Thyroid FNA Analysis. Indexing Status Subject indexing assigned by CRD MeSH Humans; Thyroid Gland Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32018000080 Date abstract record published 15/02/2018 |